Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, achieves superior glycemic control and weight loss compared to selective GLP-1 agonists by leveraging imbalanced receptor engagement and biased GLP-1 signaling that favors cAMP generation over beta-arrestin recruitment.
Tirzepatide is a once-weekly injection for Type 2 Diabetes that works by activating both GIP and GLP-1 receptors. It is designed to maximize blood sugar control and weight loss while minimizing the stomach side effects often seen with other GLP-1 drugs. Clinical trials show significant improvements in blood sugar and weight loss, particularly at higher doses.
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist... signaling studies demonstrate that tirzepatide mimics the actions of native GIP at the GIP receptor but shows bias at the GLP-1 receptor to favor cAMP generation over β-arrestin recruitment... Imbalance toward GIP receptor, combined with distinct signaling properties at the GLP-1 receptor, together may account for the promising efficacy of this investigational agent.
Why this rating
Strong preclinical mechanistic data (in vitro/in vivo) supported by early-phase clinical trial results (Phase 2b), though Phase 3 data is pending.
Source
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al. · JCI Insight · 2020
DOI 10.1172/jci.insight.140532
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →